476PUpdated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

ConclusionsIn line with the primary data, these results at an additional 5 months of follow-up show that entrectinib induced clinically meaningful, durable systemic and intracranial responses in pts with NTRK+ solid tumours.Clinical trial identificationALKA, EudraCT: 2012-000148-88 STARTRK-1, NCT02097810 STARTRK-2, NCT02568267.Editorial acknowledgementLaura Vergoz and Charlotte Kennerley, PhD of Gardiner-Caldwell Communications and was funded by F. Hoffmann-La Roche.Legal entity responsible for the studyF. Hoffman-La Roche.FundingF. Hoffman-La Roche.DisclosureC. Rolfo: Leadership role: Educational Committee Member: IALSC - Vice President; ISLB; Educational Chair: OLA Oncology Latin America Association - Faculty for ASCO International; Scientific COmmittee Member at ESO; Membership Committee Officer ESMO; Speaker Bureau / Expert testimony: MSD; GuardantHealth; Mylan; Research grant / Funding (institution): Antwerp University Hospital: Novartis; Sanofi; Non-remunerated activity/ies: Oncompass Steering scientific committee: OncoDNA; Research collaboration, no renumeration: Exesomes; Research collaboration no renumeration: GuardantHealth. R. Dziadziuszko: Advisory / Consultancy, Officer / Board of Directors: Roche, Bristol-Myers Squibb, Merck, AstraZeneca, Pfizer, Novartis; Research grant / Funding (self), Research grant / Funding (institution): Roche, Bristol-Myers Squibb, Merck, AstraZeneca, Pfizer, Novartis, Boehringer-Ingelheim, Clovis; Travel / Accommodation / Expenses: Roch...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research